Natera Inc NTRA
News
Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer
Natera Announces Leadership Transition
Natera Reports Third Quarter 2026 Financial Results
Signatera™ Monitoring During First-Line Immunotherapy Showed ctDNA Clearance is Associated with Long-Term Survival Across Four Metastatic Cancers
Signatera™ in Head and Neck Cancer: Three New Publications Demonstrate Strong Clinical Performance and Actionability
Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma
Natera to Report its Third Quarter Results on November 5, 2026
Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer
Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™
ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology
Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay
Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM
New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma